Almac IXRS 3 vs Veeva RTSM(RTSM / IRT)

Sponsors and CROs choosing a randomization and trial supply management (RTSM, also called IRT) system for interventional trials.

Scope Sponsors and CROs choosing an RTSM/IRT system to randomize participants and manage investigational product supply in interventional trials. Site-side pharmacy tools and stand-alone supply planning software are out of scope.

Guide updated How we compare

Compare within RTSM / IRT

Study fit, side by side

These notes describe the products in the RTSM / IRT guide.

Almac IXRS 3

Best for
Sponsors who also use Almac for clinical packaging and distribution and want IRT, forecasting and logistics from one group
What to consider
Almac's IXRS 3 links to Almac's own clinical supply, SupplyWise forecasting and distribution services, and supports direct-to-patient workflows. Almac reports about 2,000 trials run on IXRS. Its public pages give no build timeline, name few randomization methods and show no named security certification.
Read product profile

Veeva RTSM

Best for
Sponsors standardizing on the Veeva Clinical Platform who want RTSM connected to Veeva EDC, eCOA and CTMS
What to consider
Veeva RTSM lists a broad set of randomization schemas and productized connections to Veeva EDC, eCOA and CTMS, and a top-20 biopharma chose it as its enterprise standard in fiscal 2026. Public material does not describe direct-to-patient shipping or a dedicated forecasting tool, and no build timeline is published.
Read product profile

Compare the features

Both products use the same category definitions. Product order is editorial; products are not ranked.

Full RTSM / IRT feature comparison

Single and double checks describe documented support for an individual feature. Double checks use the extended definition for that feature. Unknown means the available evidence does not establish support.

Expand a feature definition or support note for context and its original source.

Almac IXRS 3 vs Veeva RTSM (RTSM / IRT): category feature evidence and sources. Products are not ranked.
Category featureAlmac IXRS 3Veeva RTSM
Randomization and blinding
Feature definitions
Supported
Randomization or blinding workflows are stated.
Extended support
Named allocation methods include minimization or dynamic allocation.
Supported

Almac describes simple to complex adaptive designs with enrollment caps, cohorts and blinding protection, but does not name allocation methods.

Source
About this support label

Adaptive designs and blinding protection establish base support; allocation methods are not named.

Extended support

Veeva lists static, stratified, dynamic/minimization, forced and adaptive schemas, re-randomization, capping and sentinel dosing.

Source
About this support label

Named methods explicitly include dynamic allocation and minimization.

Trial supply management
Feature definitions
Supported
Drug inventory, dispensing, shipping or resupply workflows are documented.
Extended support
Supply forecasting and direct-to-patient delivery (shipping or dispensing) are both documented.
Extended support

IXRS 3 documents resupply strategy, expiry and depot management, Almac's SupplyWise integrates demand forecasting with the IRT, and an Almac datasheet (Clinical Leader, August 2025) describes direct-to-patient workflows.

Source
About this support label

Resupply and SupplyWise forecasting combine with documented direct-to-patient workflows.

Supported

Veeva documents threshold, predictive and just-in-time resupply with expiry buffers and accountability, but no direct-to-patient shipping or separate forecasting tool.

Source
About this support label

Predictive resupply establishes base support; direct-to-patient shipping is not documented.

Study build speed and mid-study changes
Feature definitions
Supported
Study setup or post-go-live study changes are described.
Extended support
Study setup is described, and post-go-live changes explicitly avoid interrupting live study use.
Supported

Almac describes a controlled-agile build with visual requirements tools, but publishes no build timeline or mid-study change process.

Source
About this support label

Visual study build is described; a build timeline and mid-study change process are not published.

Supported

Authorized users can switch on cohorts and change limits mid-study, and Veeva says design-change amendments often take days rather than weeks; no initial build timeline is published.

Source
About this support label

Mid-study cohort and limit changes are stated; an initial build timeline and uninterrupted changes are not established.

Integrations and platform
Feature definitions
Supported
Integration or data exchange with another system or application is described.
Extended support
Integration with a clinical-trial application plus an API for integration are both stated.
Extended support

Almac lists pre-built connectors and REST, SOAP and secure file integrations with EDC, CTMS, clinical supplies and central labs, but has no EDC or eCOA of its own.

Source
About this support label

EDC/CTMS connectors are documented with REST and SOAP integrations.

Supported

Productized connections send data to Veeva EDC, eCOA and DQS and take site data from Veeva CTMS, and the brief cites third-party EDC and shipping-provider connections.

Source
About this support label

Native and external trial-system connections establish base support; an API is not stated in this note.

Compliance and security evidence
Feature definitions
Supported
Relevant trial compliance or security controls are stated, with their scope identified.
Extended support
Relevant trial controls and a publicly accessible ISO certificate or SOC audit report covering the product or vendor are documented.
Supported

Almac states its IXRS University training module is validated and 21 CFR Part 11 compliant; we found no named ISO 27001 or SOC 2 attestation for Clinical Technologies.

Source
About this support label

The Part 11 statement is limited to IXRS University training; ISO/SOC evidence was not found.

Supported

Veeva's trust page lists ISO 27001 audits and a SOC 2 Type II report, but we found no RTSM-specific Part 11 or Annex 11 statement.

Source
About this support label

Vendor security audits are listed; RTSM-specific trial controls and public document access are not established.

Track record
Feature definitions
Supported
Published product or wider-platform adoption, or a named clinical-research deployment.
Extended support
Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.
Extended support

Almac's media kit reports 2,000 clinical trials and over 2 million patients on IXRS, in more than 85 countries (undated kit).

Source
About this support label

Product-specific trial and patient figures are reported across a stated country count.

Supported

Veeva reports that a top-20 biopharma selected Veeva RTSM as its enterprise standard (fiscal 2026); no total study or customer count for RTSM is published.

Source
About this support label

An enterprise-standard selection provides base track-record evidence; product-specific adoption figures are not published.

The guide update date reflects guide edits. Vendor statements are attributed in the evidence.

Keep the category in view

Compare these products with the other tools in the RTSM / IRT guide using the same feature definitions.

More RTSM / IRT comparisons featuring one of these products.